Jazz Pharmaceuticals PLC (JAZZ) FinancialsJAZZFinancialJazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC (JAZZ) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Xywav, accounting for 39.0% of total sales, equivalent to $471.20M. Other significant revenue streams include Epidiolex/epidyolex and Zepzelca. Understanding this composition is critical for investors evaluating how JAZZ navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Jazz Pharmaceuticals PLC maintains a gross margin of 76.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.91%, while the net margin is 15.96%. These profitability ratios, combined with a Return on Equity (ROE) of 22.07%, provide a clear picture of how effectively JAZZ converts its operational activities into shareholder value.

In the context of the broader market, JAZZ competes directly with industry leaders such as ASND and HCM. With a market capitalization of $16.30B, it holds a leading position in the sector. When comparing efficiency, JAZZ's gross margin of 76.30% stands against ASND's 91.85% and HCM's 45.32%. Such benchmarking helps identify whether Jazz Pharmaceuticals PLC is trading at a premium or discount relative to its financial performance.

The company has shown a solid revenue growth trajectory, with total revenue increasing from $1.06 billion in Q1 2026 to $1.21 billion in Q2 2026. The gross margin has also improved significantly, reaching 76.30% in Q2 2026, which is a positive indicator of profitability.